MX2011000768A - Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos. - Google Patents

Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.

Info

Publication number
MX2011000768A
MX2011000768A MX2011000768A MX2011000768A MX2011000768A MX 2011000768 A MX2011000768 A MX 2011000768A MX 2011000768 A MX2011000768 A MX 2011000768A MX 2011000768 A MX2011000768 A MX 2011000768A MX 2011000768 A MX2011000768 A MX 2011000768A
Authority
MX
Mexico
Prior art keywords
antibodies
relates
same
neutralizing antibodies
influenza viruses
Prior art date
Application number
MX2011000768A
Other languages
English (en)
Spanish (es)
Inventor
Antonio Lanzavecchia
Original Assignee
Inst Research In Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Research In Biomedicine filed Critical Inst Research In Biomedicine
Publication of MX2011000768A publication Critical patent/MX2011000768A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2011000768A 2008-07-25 2009-07-27 Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos. MX2011000768A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8383808P 2008-07-25 2008-07-25
US18158209P 2009-05-27 2009-05-27
PCT/IB2009/006623 WO2010010467A2 (en) 2008-07-25 2009-07-27 Neutralizing anti-influenza a virus antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2011000768A true MX2011000768A (es) 2011-10-05

Family

ID=41570664

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011000768A MX2011000768A (es) 2008-07-25 2009-07-27 Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
MX2011000767A MX2011000767A (es) 2008-07-25 2009-07-27 Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011000767A MX2011000767A (es) 2008-07-25 2009-07-27 Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.

Country Status (20)

Country Link
US (2) US8685402B2 (https=)
EP (2) EP2313112B1 (https=)
JP (3) JP5607620B2 (https=)
KR (2) KR101732056B1 (https=)
CN (2) CN102164613B (https=)
AU (2) AU2009275226B2 (https=)
BR (1) BRPI0911699B8 (https=)
CA (2) CA2733218A1 (https=)
CO (1) CO6341572A2 (https=)
CR (2) CR20110079A (https=)
EC (1) ECSP11010823A (https=)
ES (1) ES2662519T3 (https=)
GT (1) GT201100023A (https=)
IL (2) IL210772A0 (https=)
MA (1) MA32577B1 (https=)
MX (2) MX2011000768A (https=)
NZ (2) NZ590890A (https=)
RU (1) RU2553325C2 (https=)
WO (2) WO2010010467A2 (https=)
ZA (2) ZA201101113B (https=)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
WO2010010467A2 (en) * 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
WO2011111966A2 (en) * 2010-03-08 2011-09-15 Celltrion, Inc. Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
ES2687706T3 (es) * 2010-06-17 2018-10-26 Trellis Bioscience, Llc Anticuerpos útiles en la inmunización pasiva contra la gripe
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012045001A2 (en) * 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
EP2699688A1 (en) 2011-04-20 2014-02-26 The Trustees Of The University Of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
DK2731967T3 (en) 2011-07-14 2017-01-16 Janssen Vaccines & Prevention Bv HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA A VIRUS FROM PHYLOGENETIC GROUP 1 AND PHYLOGENETIC GROUP 2 AND INFLUENZA B VIRUS
CN107417789A (zh) * 2011-07-18 2017-12-01 生物医学学会 中和抗甲型流感病毒抗体及其用途
HRP20190714T1 (hr) * 2011-07-18 2019-06-14 Institute For Research In Biomedicine Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
CN104114186B (zh) * 2011-08-03 2017-05-03 儿童医疗中心有限公司 识别流行性感冒血凝素的受体‑结合袋状结构的广泛中和人类抗体
EP2748184A1 (en) * 2011-08-27 2014-07-02 Universität Zürich Multi-strain-reactive antibodies for therapy and diagnosis of influenza
MX350282B (es) 2011-09-30 2017-09-01 Celltrion Inc Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas.
EP2768858B1 (en) * 2011-10-18 2018-08-01 Emory University Antibodies directed against influenza
KR20130059721A (ko) * 2011-11-29 2013-06-07 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
JP6325451B2 (ja) 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー Ａ型インフルエンザに特異的な抗体
ES2686526T3 (es) * 2011-12-05 2018-10-18 Trellis Bioscience, Llc Anticuerpos útiles en la inmunización pasiva contra la influenza
WO2013088367A1 (en) * 2011-12-12 2013-06-20 Novartis Ag Assay for influenza virus hemagglutinins
KR101749316B1 (ko) 2011-12-15 2017-06-21 (주) 에이프로젠 Ｈ１ｎ１―감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
RU2502745C2 (ru) * 2011-12-30 2013-12-27 Общество с ограниченной ответственностью "Технофарма" Наноантитело "anti-flu", рекомбинантные вирусные векторы и фармацевтические композиции для профилактики и терапии гриппа типа а
AU2013229488B2 (en) * 2012-03-08 2017-12-07 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
HK1207970A1 (en) 2012-05-10 2016-02-19 Massachusetts Institute Of Technology Agents for influenza neutralization
US9969794B2 (en) * 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
CN103665156B (zh) * 2012-09-14 2016-08-03 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的结合分子3e1
CN103665154B (zh) * 2012-09-14 2016-08-03 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的中和分子3c4
CN103665155B (zh) * 2012-09-14 2016-07-06 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的中和分子1f2
CN103665157B (zh) * 2012-09-14 2016-06-29 中国科学院上海生命科学研究院 一种抗流感病毒广谱中和性的中和分子1c4
SG10201700488QA (en) 2012-11-13 2017-02-27 Genentech Inc Anti-hemagglutinin antibodies and methods of use
US11827693B2 (en) 2013-03-14 2023-11-28 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
KR20140118682A (ko) * 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
CN104098692B (zh) * 2013-04-02 2018-11-30 厦门大学 识别流感病毒血凝素蛋白ha1结构域的广谱单克隆抗体
EP3733244A1 (en) * 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof
EP3070167A4 (en) * 2013-11-06 2017-06-07 Osaka University Antibody having broad neutralizing activity in group 1 influenza a virus
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP6712428B2 (ja) 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
CN104892753B (zh) * 2014-03-07 2019-11-29 神州细胞工程有限公司 一种中和人感染h7n9甲型流感病毒的抗体及其用途
PE20170261A1 (es) 2014-05-13 2017-04-12 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos
AU2015289831B2 (en) * 2014-07-14 2021-01-28 The Penn State Research Foundation Compositions and methods for targeting of the surfactant protein a receptor
CN119161468A (zh) 2014-07-15 2024-12-20 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
JPWO2016010160A1 (ja) * 2014-07-18 2017-06-01 国立感染症研究所長 抗インフルエンザウイルス抗体及びその利用
WO2016089181A1 (ko) * 2014-12-05 2016-06-09 (주)셀트리온 1 이상의 인플루엔자 바이러스 중화 결합 분자를 포함하는 애주번트 조성물 및 이를 포함하는 백신 조성물
US20180008702A1 (en) 2014-12-05 2018-01-11 Celltrion Inc. Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EA201792500A1 (ru) * 2015-05-13 2018-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Aav-опосредованная экспрессия антител против гриппа и способы их использования
CN113480640B (zh) * 2015-06-01 2024-07-30 免疫医疗有限责任公司 中和抗流感结合分子及其用途
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2017123685A1 (en) 2016-01-13 2017-07-20 Medimmune, Llc Method of treating influenza a
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
EP3498263B1 (en) * 2016-08-10 2023-11-29 Celltrion Inc. Stable liquid pharmaceutical preparation for anti-influenza virus antibody
JP2017086068A (ja) * 2016-10-31 2017-05-25 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
RU2656142C1 (ru) * 2016-12-30 2018-05-31 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA1FI6-ht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IGA1
RU2664184C2 (ru) * 2016-12-30 2018-08-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA1FI6-Intht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IgA1
RU2671477C2 (ru) * 2016-12-30 2018-10-31 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBiPr-ABIgA2m1F16-ht ДЛЯ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИММУНОГЛОБУЛИНА А ИЗОТИПА IGA2m1
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
CA3052487A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Influenza vaccines based on aav vectors
JP7455579B2 (ja) 2017-02-28 2024-03-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規アデノ随伴ウイルス（ａａｖ）クレードｆベクター及びその用途
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
US11685934B2 (en) 2017-09-18 2023-06-27 Amyris, Inc. Methods for genomic integration for Kluyveromyces host cells
WO2019055481A1 (en) * 2017-09-18 2019-03-21 Amyris, Inc. METHODS OF GENOMIC INTEGRATION IN PICHIA AND OTHER HOST CELLS
CN109988236B (zh) * 2017-12-30 2022-04-01 中国科学院天津工业生物技术研究所 一种流感病毒抗体的应用
SMT202200354T1 (it) * 2018-01-23 2022-09-14 Janssen Vaccines & Prevention Bv Vaccino per virus dell'influenza e suoi usi
JP6622825B2 (ja) * 2018-01-25 2019-12-18 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
KR102820941B1 (ko) 2018-01-26 2025-06-16 리제너론 파마슈티칼스 인코포레이티드 인플루엔자 헤마글루티닌에 대한 인간 항체
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
CA3128502A1 (en) * 2019-02-01 2020-08-06 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
EP3936147A4 (en) 2019-03-04 2022-09-28 JAPAN as represented by DIRECTOR GENERAL of National Institute of Infectious Diseases METHOD OF MANUFACTURE OF AN INFLUENZA HA-SPLIT VACCINE
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
JP2020048568A (ja) * 2019-11-22 2020-04-02 インスティテュート・フォー・リサーチ・イン・バイオメディシンＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｒｅｓｅａｒｃｈ Ｉｎ Ｂｉｏｍｅｄｉｃｉｎｅ Ａ型インフルエンザウイルス中和抗体及びその使用法
CN115551885A (zh) 2019-12-11 2022-12-30 威特拉公司 用于治疗和预防流感的组合物和方法
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
CN111825763B (zh) * 2020-07-15 2022-04-19 扬州大学 流感病毒ha蛋白茎部特异性单克隆抗体及其制备方法和应用
CN114181303B (zh) * 2020-09-14 2022-12-23 东莞市朋志生物科技有限公司 抗甲型流感病毒的抗体和试剂盒
TW202237850A (zh) 2020-12-01 2022-10-01 賓州大學委員會 具有組織特異性靶向基序的新穎構成物及含有其之組成物
CN117881786A (zh) 2021-04-27 2024-04-12 世代生物公司 表达治疗性抗体的非病毒dna载体及其用途
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
KR20240088574A (ko) 2022-11-21 2024-06-20 (주)샤페론 인플루엔자 바이러스에 대한 단일 도메인 항체 및 이의 용도
CN119930806B (zh) * 2025-01-21 2025-12-02 中国医学科学院病原生物学研究所 一种甲型流感病毒中和抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US630064A (en) * 1899-02-10 1899-08-01 William Martindale Safety-hook.
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
RU2031941C1 (ru) * 1991-03-14 1995-03-27 Научно-исследовательский институт гриппа РАМН Штамм вируса гриппа а(нini) для получения живой гриппозной интраназальной вакцины для взрослых и детей
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
AU8063798A (en) 1997-06-19 1999-01-04 Regents Of The University Of California, The Secretory immunoglobulin produced by single cells and methods for making and using same
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US8101553B1 (en) * 2000-02-22 2012-01-24 Medical & Biological Laboratories Co., Ltd. Antibody library
WO2004007667A2 (en) 2002-07-11 2004-01-22 The General Hospital Corporation Polynucleotide and polypeptide fat metabolism regulators and uses thereof
CN1756562A (zh) * 2003-03-07 2006-04-05 麦克公司 流感病毒疫苗
RU2390351C2 (ru) 2003-08-11 2010-05-27 Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
EP2024393A2 (en) * 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
JP5161882B2 (ja) * 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
CN101522716B (zh) 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
US7718774B2 (en) * 2006-11-08 2010-05-18 Macrogenics, Inc. TES7 and antibodies that bind thereto
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
WO2008110937A2 (en) 2007-03-13 2008-09-18 Humabs Llc Antibodies against h5n1 strains of influenza a virus
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
US8871207B2 (en) * 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
WO2010010467A2 (en) * 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof

Also Published As

Publication number Publication date
EP2313112A2 (en) 2011-04-27
JP5607620B2 (ja) 2014-10-15
EP2313433A2 (en) 2011-04-27
US9340603B2 (en) 2016-05-17
MX2011000767A (es) 2011-09-21
IL210772A0 (en) 2011-03-31
MA32577B1 (fr) 2011-08-01
AU2009275226B2 (en) 2015-05-14
WO2010010466A2 (en) 2010-01-28
JP6022515B2 (ja) 2016-11-09
BRPI0911699B1 (pt) 2020-11-17
KR20110047193A (ko) 2011-05-06
RU2011105062A (ru) 2012-08-27
CN102164613B (zh) 2014-11-26
CA2731686A1 (en) 2010-01-28
ES2662519T3 (es) 2018-04-06
GT201100023A (es) 2013-12-10
CR20110084A (es) 2011-07-18
WO2010010466A3 (en) 2010-07-29
KR20110049802A (ko) 2011-05-12
ZA201101113B (en) 2012-08-29
ECSP11010823A (es) 2011-08-31
JP2011528902A (ja) 2011-12-01
KR101732056B1 (ko) 2017-05-02
RU2553325C2 (ru) 2015-06-10
BRPI0911699B8 (pt) 2023-02-28
NZ590891A (en) 2013-03-28
NZ590890A (en) 2013-05-31
CA2733218A1 (en) 2010-01-28
AU2009275226A1 (en) 2010-01-28
JP2011528901A (ja) 2011-12-01
JP2014237714A (ja) 2014-12-18
EP2313112B1 (en) 2017-12-27
US8685402B2 (en) 2014-04-01
HK1161110A1 (en) 2012-08-24
CN102216327A (zh) 2011-10-12
CR20110079A (es) 2011-07-18
CA2731686C (en) 2020-04-07
WO2010010467A2 (en) 2010-01-28
AU2009275227A1 (en) 2010-01-28
BRPI0911699A2 (pt) 2014-09-23
US20100086555A1 (en) 2010-04-08
CN102164613A (zh) 2011-08-24
CO6341572A2 (es) 2011-11-21
WO2010010467A3 (en) 2010-12-16
US20100080813A1 (en) 2010-04-01
IL210771A0 (en) 2011-03-31
ZA201101150B (en) 2012-08-29

Similar Documents

Publication Publication Date Title
MX2011000768A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
MX352338B (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
CL2021002994A1 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. (divisional de la solicitud no. 201900067)
CY1124043T1 (el) Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων
EA201490288A1 (ru) Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
MX2017010009A (es) Moléculas de unión dirigidas contra hemaglutinina de virus influenza y usos de las mismas.
MX360056B (es) Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
MX382043B (es) Anticuerpo anti-influenza a neutralizantes y usos de los mismos.
EA201500854A1 (ru) Композиция, содержащая по меньшей мере две связывающие молекулы, нейтрализующие вирус гриппа а
CO7151488A2 (es) Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos
MX386403B (es) Anticuerpos humanos para hemaglutinina de influenza.
EA029939B8 (ru) Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение
MX366180B (es) Nuevos agentes de union a ha.
BR112014030466A2 (pt) peptídeos derivados de proteínas virais para uso como imunógenos e reagentes de dosagem
BR112014013640A2 (pt) anticorpos úteis na imunização passiva contra influenza
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
BR112014023063A2 (pt) anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos
BR112016018082A2 (pt) ?anticorpos úteis na imunização passiva de influenza e composições, combinações e métodos para uso dos mesmos?
MX392761B (es) Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
CL2011003002A1 (es) Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
ECSP21039816A (es) Anticuerpos monoclonales antirrábicos y cóctel de estos
EA201792482A1 (ru) Соединения-пептидомиметики, нейтрализующие вирус гриппа
TN2011000028A1 (en) Neutralizing anti-influenza a virus antibodies and uses therof
ES2387243A1 (es) Péptidos para detectar estirpes de lentivirus
CU20140006A7 (es) Moléculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenético 1 y grupo filogenético 2 y virus de la influenza b

Legal Events

Date Code Title Description
FA Abandonment or withdrawal